Sfoglia per Autore  

Opzioni
Mostrati risultati da 41 a 60 di 107
Titolo Tipologia Data di pubblicazione Autori File
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 01 - Articolo su rivista 2018 Mologni, LucaGIANNI, STEFANOPasserini, Carlo Gambacorti +
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 02 - Intervento a convegno 2018 GEETA, GEETARedaelli, SCeccon, MGambacorti-Passerini, CMologni, L +
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 01 - Articolo su rivista 2018 Redaelli, SaraCeccon, MonicaSharma, Geeta GMastini, CristinaMauri, MarioMassimino, LucaCordani, NicolettaFarina, FrancescaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 01 - Articolo su rivista 2018 Ceccon, MonicaMauri, MarioMassimino, LucaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 01 - Articolo su rivista 2018 Mologni, LSharma, GGViltadi, MMassimino, LCitterio, SPurgante, SRaman, HPirola, APiazza, RGambacorti-Passerini, C +
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead 01 - Articolo su rivista 2017 Mologni, Luca +
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 02 - Intervento a convegno 2017 Farina, FCeccon, MMori, SVerga, LBorin, LMMologni, LFontana, DGEETA, GEETAPiazza, RGambacorti-Passerini, C
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 01 - Articolo su rivista 2017 MOLOGNI, LUCAMAGISTRONI, VERAGAMBACORTI PASSERINI, CARLO +
RET kinase inhibitors: a review of recent patents (2012–2015) 01 - Articolo su rivista 2017 MOLOGNI, LUCAGAMBACORTI PASSERINI, CARLO +
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 01 - Articolo su rivista 2017 Mastini, CristinaMologni, Luca +
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 01 - Articolo su rivista 2017 Mologni, LPiazza, RKhandelwal, PGambacorti-Passerini, C +
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 02 - Intervento a convegno 2017 Mastini, CMologni, L +
Targeting drug resistance mutations: Discovery of EUD-GK-91 chemical series 02 - Intervento a convegno 2016 Bernardi, AMologni, L +
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 01 - Articolo su rivista 2016 CECCON, MONICAMOLOGNI, LUCABOMBELLI, SILVIARIGOLIO, ROBERTACASATI, COSTANZAMASTINI, CRISTINAGAMBACORTI PASSERINI, CARLO +
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 01 - Articolo su rivista 2016 MOLOGNI, LUCA +
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 02 - Intervento a convegno 2016 Piazza, RMologni, LRamazzotti, DSpinelli, RPirola, AMagistroni, VSharma, NKHANDELWAL, PRAVEENGambacorti-Passerini, C +
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 01 - Articolo su rivista 2016 REDAELLI, SARACECCON, MONICAANTOLINI, LAURARIGOLIO, ROBERTAPIROLA, ALESSANDRAPERONACI, MARCOGAMBACORTI PASSERINI, CARLOMOLOGNI, LUCA
Expanding the portfolio of anti-ALK weapons 01 - Articolo su rivista 2015 MOLOGNI, LUCA
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 02 - Intervento a convegno 2015 Ceccon, MMologni, LBombelli, SRigolio, RCASATI, COSTANZAGambacorti Passerini, C +
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 02 - Intervento a convegno 2015 Redaelli, SCeccon, MPirola, APeronaci, MGambacorti-Passerini, CMologni, L
Mostrati risultati da 41 a 60 di 107
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile